专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US4512013A Simultaneous transmission of speech and data over an analog channel 失效
标题翻译：通过模拟通道同时传输语音和数据
公开(公告)号：US4512013A
公开(公告)日：1985-04-16
申请号：US483879
申请日：1983-04-11
申请人： Randy D. Nash , Wai C. Wong
发明人： Randy D. Nash , Wai C. Wong
IPC分类号： H04J1/00 , H04J1/20 , H04L27/34 , H04M11/06 , H04J1/02
CPC分类号： H04J1/20 , H04L27/3483 , H04M11/062
摘要： The present invention relates to a technique for transmitting an entire analog speech signal and a modulated data signal over a transmission channel such as a common analog telephone speech channel. The present technique multiplexes the entire modulated data signal within the normal analog speech signal frequency band where the speech is present and its signal power density characteristic is at a low level. Separation of the speech and data signals at the receiver is effected by recovering the modulation carrier frequency and demodulating the received signal to recover the data signal. The data signal is then remodulated with the recovered carrier and is convolved with an arbitrary channel impulse response in an adaptive filter whose output signal is subtracted from the received composite data and speech signal to generate the recovered speech signal. To improve the recovered speech signal, a least mean square algorithm is used to update the arbitrary channel impulse response output signal of the adaptive filter.
摘要翻译：本发明涉及通过诸如公共模拟电话语音信道的传输信道发送整个模拟语音信号和调制数据信号的技术。本技术将整个调制数据信号复用在语音存在的正常模拟语音信号频带内，其信号功率密度特性处于低电平。通过恢复调制载波频率并解调接收到的信号以恢复数据信号来实现接收机处的语音和数据信号的分离。数据信号然后用恢复的载波再调制，并在自适应滤波器中与任意信道脉冲响应进行卷积，其中从接收到的合成数据和语音信号中减去其输出信号以产生恢复的语音信号。为了改善恢复的语音信号，使用最小均方算法来更新自适应滤波器的任意信道脉冲响应输出信号。

2. 发明授权

US06727257B1 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US06727257B1
公开(公告)日：2004-04-27
申请号：US09730458
申请日：2000-12-05
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski , Bharat Lagu , Shou Wu Miao
IPC分类号： C07D40106
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds of the following formula: wherein A is which are selective antagonists for human &agr;1C receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotence, cardiac arrhythmia and for the treatment of any disease where antagonism of the &agr;1C receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及下式的二氢嘧啶化合物：其中A是人α1C受体的选择性拮抗剂。本发明还涉及这些化合物用于降低眼内压，抑制胆固醇合成，放松下尿路组织，治疗良性前列腺增生，阳ence，心律失常以及用于治疗任何α1C受体拮抗作用的疾病有用本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

3. 发明授权

US06214853B1 Selective NPY (Y5) antagonists (bicyclics) 有权
标题翻译：选择性NPY（Y5）拮抗剂（双环）
公开(公告)号：US06214853B1
公开(公告)日：2001-04-10
申请号：US09343633
申请日：1999-06-30
申请人： Mohammad R. Marzabadi , Wai C. Wong , Yasuchika Yamaguchi , Stewart A. Noble
发明人： Mohammad R. Marzabadi , Wai C. Wong , Yasuchika Yamaguchi , Stewart A. Noble
IPC分类号： A01K31427
CPC分类号： C07D277/60 , C07D277/42 , C07D417/12 , C07D513/04
摘要： This invention is directed to bicyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

4. 发明授权

US06620815B1 Oxazolidinones and uses thereof 失效
标题翻译：恶唑烷酮及其用途
公开(公告)号：US06620815B1
公开(公告)日：2003-09-16
申请号：US09636518
申请日：2000-08-10
申请人： Bharat Lagu , T. G. Murali Dhar , Dhanapalan Nagarathnam , Yoon T. Jeon , Mohammad R. Marzabadi , Wai C. Wong , Charles Gluchowski
发明人： Bharat Lagu , T. G. Murali Dhar , Dhanapalan Nagarathnam , Yoon T. Jeon , Mohammad R. Marzabadi , Wai C. Wong , Charles Gluchowski
IPC分类号： A61K31496
CPC分类号： C07D263/52 , A61K31/58 , C07D263/26 , C07D401/12 , C07D401/14 , C07D413/12 , C07D413/14 , A61K31/535 , A61K31/495 , A61K31/445 , A61K2300/00
摘要： This invention is directed to oxazolidinone compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为人α1A受体的选择性拮抗剂的恶唑烷酮化合物。本发明还涉及这些化合物降低眼内压，抑制胆固醇合成，松弛下尿路组织，治疗良性前列腺增生，阳ency，心律失常以及治疗任何α1A受体拮抗作用的疾病的用途可能是有用的本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

5. 发明授权

US06211198B1 Dihydropyridines and new uses thereof 失效
标题翻译：二氢吡啶类及其新用途
公开(公告)号：US06211198B1
公开(公告)日：2001-04-03
申请号：US09098699
申请日：1998-06-15
申请人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
发明人： Charles Gluchowski , John M. Wetzel , George Chiu , Mohammed R. Marzabadi , Wai C. Wong , Dhanapalan Nagarathnam
IPC分类号： A61K314545
CPC分类号： C07D401/12 , C07D211/90 , C07D401/14 , C07D405/14 , C07D471/04 , C07D471/10 , C07F7/0812
摘要： The invention provides a method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the structure: wherein Y is —(CH2)n—, where n is 1, 2, 3, 4 or 5; —(CH2)h—O—(CH2)k—, where h and k are independently the same or different and are 2, 3 or 4; —(CH2)h—CH═CH—(CH2)k—; or —(CH2)h—C≡C—(CH2)k—, where h and k are independently the same or different and are 1, 2, 3 or 4; wherein Z is O, NH, or CH2; wherein R1 is a linear or branched chain alkyl, alkoxyalkyl or arylalkyl group; wherein R2 and R4 are independently the same or different and are H, or a linear or branched chain alkyl group; wherein R3 is H, a linear or branched chain alkyl, alkoxy, alkoxyalkyl or acyl group; and wherein R5 and R6 are independently the same or different and are H, OH, Cl, Br, F, NO2, CN, CF3, or NH2, or a linear or branched chain alkyl, alkoxy, alkoxycarbonyl, acyl, alkylsulfoxide, alkylsulfone, or mono- or dialkylamino group. Other active compounds containing one, two or three rings are also disclosed as well as pharmaceutical compositions prepared therefrom and methods of use in the treatment of BPH, inhibition of cholesterol synthesis, and reduction of intraocular pressure.
摘要翻译：本发明提供一种治疗受试者的良性前列腺增生的方法，其包括向受试者施用治疗有效量的具有以下结构的化合物：其中Y为 - （CH 2）n - ，其中n为1,2,3,4 或5; - （CH 2）h -O-（CH 2）k - ，其中h和k独立地相同或不同，为2,3或4; - （CH 2）h -CH = CH-（CH 2）k - ; 或 - （CH 2）h -C = C-（CH 2）k - ，其中h和k独立地相同或不同，为1,2,3或4; 其中Z是O，NH或CH 2; 其中R1是直链或支链烷基，烷氧基烷基或芳基烷基; 其中R2和R4独立地相同或不同，为H或直链或支链烷基; 其中R3是H，直链或支链烷基，烷氧基，烷氧基烷基或酰基; 并且其中R 5和R 6独立地相同或不同，为H，OH，Cl，Br，F，NO 2，CN，CF 3或NH 2，或直链或支链烷基，烷氧基，烷氧基羰基，酰基，烷基亚砜，烷基砜，或一或二烷基氨基。还公开了含有一个，两个或三个环的其它活性化合物以及由其制备的药物组合物以及用于治疗BPH，抑制胆固醇合成和降低眼内压的方法。

6. 发明授权

US5942517A 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines 失效
标题翻译： 5-（杂环烷基）-6-芳基 - 二氢嘧啶
公开(公告)号：US5942517A
公开(公告)日：1999-08-24
申请号：US978682
申请日：1997-11-26
申请人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
发明人： Dhanapalan Nagarathnam , George Chiu , T. G. Murali Dhar , Wai C. Wong , Mohammad R. Marzabadi , Charles Gluchowski
IPC分类号： C07D239/22 , A61K20060101 , A61K31/505 , A61K31/506 , A61P3/06 , A61P9/06 , A61P13/02 , A61P13/08 , A61P15/00 , A61P25/04 , A61P43/00 , C07D20060101 , C07D239/30 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D453/02 , C07D491/04 , C07D491/048 , C07D521/00 , C07D239/32
CPC分类号： C07D239/30 , C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/14 , C07D413/14 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds which are selective antagonists for human .alpha..sub.1C receptors and which have the structure: ##STR1## wherein A is aryl; R.sub.1, R.sub.2 and R.sub.3 are alkyl or heteroalkyl; R.sub.4 is heterocyclic alkyl; and X is S, O or NR.sub.3. This invention also relates to use of these compounds for the treatment of benign prostatic hyperplasia and other diseases where antagonism of the human .alpha..sub.1C receptor is useful. The invention further provides pharmaceutical compositions comprising a therapeutically effective amount of such a compound and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为人α1C受体的选择性拮抗剂的二氢嘧啶化合物，其具有以下结构：其中A为芳基; R1，R2和R3是烷基或杂烷基; R4是杂环烷基; X为S，O或NR 3。本发明还涉及这些化合物用于治疗良性前列腺增生症和其它对人α1c受体的拮抗作用有用的其它疾病的用途。本发明还提供包含治疗有效量的这种化合物和药学上可接受的载体的药物组合物。

7. 发明授权

US06989379B1 Selective NPY (Y5) antagonists 失效
标题翻译：选择性NPY（Y5）拮抗剂
公开(公告)号：US06989379B1
公开(公告)日：2006-01-24
申请号：US10009849
申请日：2000-04-21
申请人： Mohammad R. Marzabadi , Wai C. Wong , Stewart A. Noble , Manesh N. Desai
发明人： Mohammad R. Marzabadi , Wai C. Wong , Stewart A. Noble , Manesh N. Desai
IPC分类号： C07D513/04 , C07D513/22 , A61K31/381 , A61P3/04
CPC分类号： C07D401/12 , C07D251/70 , C07D277/28 , C07D403/12 , C07D409/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D513/04
摘要： This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三嗪衍生物，双环化合物和三环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。本发明还提供了本发明化合物在制备用于治疗异常的药物组合物中的用途，其中通过降低人Y5受体的活性来减轻异常。

8. 发明授权

US06294566B1 Imidazoline derivatives and uses thereof 失效
标题翻译：咪唑啉衍生物及其用途
公开(公告)号：US06294566B1
公开(公告)日：2001-09-25
申请号：US09398861
申请日：1999-09-20
申请人： Wai C. Wong , Yoon T. Jeon , Charles Gluchowski
发明人： Wai C. Wong , Yoon T. Jeon , Charles Gluchowski
IPC分类号： A61K314168
CPC分类号： C07D401/06 , C07D233/50 , C07D401/12 , C07D403/12 , C07D471/04 , C07D491/04 , C07D495/04
摘要： This invention is directed to novel imidazole and imidazoline derivatives which are selective agonists for cloned human &agr;2 adrenergic receptors. This invention is also related to the use of these compounds for the treatment of any disease where modulation of the &agr;2 receptors may be useful. The invention further provides for a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及新的咪唑和咪唑啉衍生物，其是用于克隆的人α2肾上腺素能受体的选择性激动剂。本发明还涉及这些化合物用于治疗其中α2受体调节可能有用的任何疾病的用途。本发明还提供了包含治疗有效量的上述化合物和药学上可接受的载体的药物组合物。

9. 发明授权

US06228861B1 Dihydropyrimidines and uses thereof 失效
公开(公告)号：US06228861B1
公开(公告)日：2001-05-08
申请号：US09068782
申请日：1998-11-10
申请人： Dhanapalan Nagarathnam , Wai C. Wong , Shou Wu Miao , Charles Gluchowski , Michael A. Patane
发明人： Dhanapalan Nagarathnam , Wai C. Wong , Shou Wu Miao , Charles Gluchowski , Michael A. Patane
IPC分类号： A61K31505
CPC分类号： C07D239/22 , C07D401/12 , C07D491/04
摘要： This invention is directed to dihydropyrimidine compounds which are selective antagonists for human &agr;1A receptors. This invention is also related to uses of these compounds for lowering intraocular pressure, inhibiting cholesterol synthesis, relaxing lower urinary tract tissue, the treatment of benign prostatic hyperplasia, impotency, cardiac arrhythmia and for the treatment of any disease where the antagonism of the &agr;1A receptor may be useful. The invention further provides a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

10. 发明授权

US06222040B1 Selective NPY (Y5) antagonists (tricyclics) 有权
标题翻译：选择性NPY（Y5）拮抗剂（三环）
公开(公告)号：US06222040B1
公开(公告)日：2001-04-24
申请号：US09343993
申请日：1999-06-30
申请人： Mohammad R. Marzabadi , Peter Bühlmayer , Heinrich Rüeger , Wai C. Wong , Yasuchika Yamaguchi , Stewart A. Noble
发明人： Mohammad R. Marzabadi , Peter Bühlmayer , Heinrich Rüeger , Wai C. Wong , Yasuchika Yamaguchi , Stewart A. Noble
IPC分类号： A61K31429
CPC分类号： C07D277/60 , C07D277/42 , C07D417/12 , C07D513/04
摘要： This invention is directed to tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.
摘要翻译：本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三环化合物。本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式